Ronald A. Williams
Known title: DirectorCIK: 0001185243
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Agilon Health Stock Moves Amid Peer Comparison. Recent market activity for Agilon Health has drawn attention to how its performance compares with other medical sector stocks this year. The company's stock is currently trading near a significant support level, which may be influencing investor sentiment. Analysts maintain a wide range of price targets, reflecting varying views on the company's future trajectory.
Transaction History
| WRBY | ▲ Buy | Grant | 13,006 | $0 | 6/8/2026 | View on chart |
| AGL | ▲ Buy | Grant | 2,133 | $0 | 6/2/2026 | View on chart |
| WRBY | ▲ Buy | Grant | 17,362 | $0 | 6/10/2025 | View on chart |
| AGL | ▲ Buy | Grant | 78,724 | $0 | 5/28/2025 | View on chart |
| WRBY | ▲ Buy | Grant | 415 | $0 | 10/18/2024 | View on chart |
| WRBY | ▲ Buy | Grant | 790 | $0 | 8/1/2024 | View on chart |
| WRBY | ▲ Buy | Grant | 19,724 | $0 | 6/7/2024 | View on chart |
| AGL | ▲ Buy | Grant | 32,119 | $0 | 5/29/2024 | View on chart |
| AGL | ▲ Buy | Option Exercise | 950,000 | $950K | 1/5/2024 | View on chart |
| AGL | ▲ Buy | Option Exercise | 150,000 | $450K | 1/5/2024 | View on chart |
| WRBY | ▲ Buy | Grant | 25,924 | $0 | 6/8/2023 | View on chart |
| AGL | ▲ Buy | Grant | 5,622 | $0 | 4/14/2023 | View on chart |
| WRBY | ▲ Buy | Grant | 16,025 | $0 | 6/9/2022 | View on chart |
| AGL | ▲ Buy | Grant | 6,936 | $0 | 4/14/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Warby Parker Reports Q2 2026 Earnings; Included in Pre‑Market Movers
Warby Parker released its Q2 2026 earnings, showing revenue growth and updated guidance. The company was also part of a group of 12 consumer discretionary stocks that moved in Monday's pre‑market session, indicating broader sector interest. These developments may influence short‑term trading activity around the stock’s support level at $24.77.
Warby Parker Reports Q2 2026 Earnings; Included in Pre‑Market Movers. Warby Parker released its Q2 2026 earnings, showing revenue growth and updated guidance. The company was also part of a group of 12 consumer discretionary stocks that moved in Monday's pre‑market session, indicating broader sector interest. These developments may influence short‑term trading activity around the stock’s support level at $24.77.